Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navenibart in Hereditary Angioedema (HAE)
NCT06842823Phase 3Active, not recruiting
- Sponsor
- Astria Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Started Mar 2025; status: active, not recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06842823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842823.